BeiGene Granted US Regulatory Nod for TEVIMBRA® to Treat Progressive or Spread Esophageal Cancer Post-Chemotherapy.

Morphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects.

Ionis has disclosed encouraging outcomes from its second-phase trial of ION224, a drug currently being tested which shows promise in addressing NASH/MASH conditions.

Pseudoephedrine Hydrochloride, a small molecule drug, acts as an α-adrenergic receptor agonist, exerting its effects through the stimulation of α-adrenergic receptors.

Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.

Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.

Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.

Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).

Pfizer Reveals Favorable Survival Data from Stage III Study of ADCETRIS® for Recurrent/Resistant Large B-cell Lymphoma Treatment.

clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.

At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.

Fenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist.